These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

537 related articles for article (PubMed ID: 12908554)

  • 1. Mutated tyrosine kinases as therapeutic targets in myeloid leukemias.
    Sattler M; Scheijen B; Weisberg E; Griffin JD
    Adv Exp Med Biol; 2003; 532():121-40. PubMed ID: 12908554
    [TBL] [Abstract][Full Text] [Related]  

  • 2. ARG tyrosine kinase activity is inhibited by STI571.
    Okuda K; Weisberg E; Gilliland DG; Griffin JD
    Blood; 2001 Apr; 97(8):2440-8. PubMed ID: 11290609
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Mechanisms of transformation by the BCR/ABL oncogene.
    Sattler M; Griffin JD
    Int J Hematol; 2001 Apr; 73(3):278-91. PubMed ID: 11345193
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Combination of the histone deacetylase inhibitor LBH589 and the hsp90 inhibitor 17-AAG is highly active against human CML-BC cells and AML cells with activating mutation of FLT-3.
    George P; Bali P; Annavarapu S; Scuto A; Fiskus W; Guo F; Sigua C; Sondarva G; Moscinski L; Atadja P; Bhalla K
    Blood; 2005 Feb; 105(4):1768-76. PubMed ID: 15514006
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Tyrosine kinase inhibitor AG1024 exerts antileukaemic effects on STI571-resistant Bcr-Abl expressing cells and decreases AKT phosphorylation.
    Deutsch E; Maggiorella L; Wen B; Bonnet ML; Khanfir K; Frascogna V; Turhan AG; Bourhis J
    Br J Cancer; 2004 Nov; 91(9):1735-41. PubMed ID: 15494718
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Tyrosine kinase inhibitor as a therapeutic drug for chronic myelogenous leukemia and gastrointestinal stromal tumor].
    Nakajima M; Toga W
    Nihon Yakurigaku Zasshi; 2003 Dec; 122(6):482-90. PubMed ID: 14639002
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Targeting PIM kinases impairs survival of hematopoietic cells transformed by kinase inhibitor-sensitive and kinase inhibitor-resistant forms of Fms-like tyrosine kinase 3 and BCR/ABL.
    Adam M; Pogacic V; Bendit M; Chappuis R; Nawijn MC; Duyster J; Fox CJ; Thompson CB; Cools J; Schwaller J
    Cancer Res; 2006 Apr; 66(7):3828-35. PubMed ID: 16585210
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Targeting mutated tyrosine kinases in the therapy of myeloid leukaemias.
    Banerji L; Sattler M
    Expert Opin Ther Targets; 2004 Jun; 8(3):221-39. PubMed ID: 15161429
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Combination of rapamycin and protein tyrosine kinase (PTK) inhibitors for the treatment of leukemias caused by oncogenic PTKs.
    Mohi MG; Boulton C; Gu TL; Sternberg DW; Neuberg D; Griffin JD; Gilliland DG; Neel BG
    Proc Natl Acad Sci U S A; 2004 Mar; 101(9):3130-5. PubMed ID: 14976243
    [TBL] [Abstract][Full Text] [Related]  

  • 10. p90RSK2 is essential for FLT3-ITD- but dispensable for BCR-ABL-induced myeloid leukemia.
    Elf S; Blevins D; Jin L; Chung TW; Williams IR; Lee BH; Lin JX; Leonard WJ; Taunton J; Khoury HJ; Kang S
    Blood; 2011 Jun; 117(25):6885-94. PubMed ID: 21527514
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Potentiation of antileukemic therapies by the dual PI3K/PDK-1 inhibitor, BAG956: effects on BCR-ABL- and mutant FLT3-expressing cells.
    Weisberg E; Banerji L; Wright RD; Barrett R; Ray A; Moreno D; Catley L; Jiang J; Hall-Meyers E; Sauveur-Michel M; Stone R; Galinsky I; Fox E; Kung AL; Griffin JD
    Blood; 2008 Apr; 111(7):3723-34. PubMed ID: 18184863
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The tyrosine kinase inhibitor CGP 57148 (ST1 571) induces apoptosis in BCR-ABL-positive cells by down-regulating BCL-X.
    Oetzel C; Jonuleit T; Götz A; van der Kuip H; Michels H; Duyster J; Hallek M; Aulitzky WE
    Clin Cancer Res; 2000 May; 6(5):1958-68. PubMed ID: 10815921
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Janus kinase 2: a critical target in chronic myelogenous leukemia.
    Samanta AK; Lin H; Sun T; Kantarjian H; Arlinghaus RB
    Cancer Res; 2006 Jul; 66(13):6468-72. PubMed ID: 16818614
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Selective cytotoxic mechanism of GTP-14564, a novel tyrosine kinase inhibitor in leukemia cells expressing a constitutively active Fms-like tyrosine kinase 3 (FLT3).
    Murata K; Kumagai H; Kawashima T; Tamitsu K; Irie M; Nakajima H; Suzu S; Shibuya M; Kamihira S; Nosaka T; Asano S; Kitamura T
    J Biol Chem; 2003 Aug; 278(35):32892-8. PubMed ID: 12815052
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmacologic mitogen-activated protein/extracellular signal-regulated kinase kinase/mitogen-activated protein kinase inhibitors interact synergistically with STI571 to induce apoptosis in Bcr/Abl-expressing human leukemia cells.
    Yu C; Krystal G; Varticovksi L; McKinstry R; Rahmani M; Dent P; Grant S
    Cancer Res; 2002 Jan; 62(1):188-99. PubMed ID: 11782377
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Requirement of Src kinases Lyn, Hck and Fgr for BCR-ABL1-induced B-lymphoblastic leukemia but not chronic myeloid leukemia.
    Hu Y; Liu Y; Pelletier S; Buchdunger E; Warmuth M; Fabbro D; Hallek M; Van Etten RA; Li S
    Nat Genet; 2004 May; 36(5):453-61. PubMed ID: 15098032
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The effects of Bcr-Abl on C/EBP transcription-factor regulation and neutrophilic differentiation are reversed by the Abl kinase inhibitor imatinib mesylate.
    Schuster C; Forster K; Dierks H; Elsasser A; Behre G; Simon N; Danhauser-Riedl S; Hallek M; Warmuth M
    Blood; 2003 Jan; 101(2):655-63. PubMed ID: 12393654
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Sole BCR-ABL inhibition is insufficient to eliminate all myeloproliferative disorder cell populations.
    Wong S; McLaughlin J; Cheng D; Zhang C; Shokat KM; Witte ON
    Proc Natl Acad Sci U S A; 2004 Dec; 101(50):17456-61. PubMed ID: 15505216
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Molecular characterization and sensitivity of STI-571 (imatinib mesylate, Gleevec)-resistant, Bcr-Abl-positive, human acute leukemia cells to SRC kinase inhibitor PD180970 and 17-allylamino-17-demethoxygeldanamycin.
    Nimmanapalli R; O'Bryan E; Huang M; Bali P; Burnette PK; Loughran T; Tepperberg J; Jove R; Bhalla K
    Cancer Res; 2002 Oct; 62(20):5761-9. PubMed ID: 12384536
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Multifaceted approach to the treatment of bcr-abl-positive leukemias.
    O'Dwyer M
    Oncologist; 2002; 7 Suppl 1():30-8. PubMed ID: 11961207
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 27.